Sutton Wealth Advisors Inc. Coherus Bio Sciences, Inc. Transaction History

Sutton Wealth Advisors Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 07, 2023	SELL	$5.89 - $10.52 $20,455 - $36,535	-3,473 Closed	0 $0
Q4 2022 Nov 07, 2023	SELL	$5.69 - $10.07 $347 - $614	-61 Reduced 1.73%	3,473 $27.5 Million
Q3 2022 Nov 07, 2023	SELL	$7.17 - $13.87 $157 - $305	-22 Reduced 0.62%	3,534 $34 Million
Q2 2022 Nov 07, 2023	BUY	$5.86 - $13.23 $13,237 - $29,886	2,259 Added 174.17%	3,556 $25.7 Million
Q1 2022 Nov 07, 2023	BUY	$10.92 - $16.41 $3,068 - $4,611	281 Added 27.66%	1,297 $16.7 Million
Q4 2021 Nov 07, 2023	BUY	$15.81 - $18.99 $7,762 - $9,324	491 Added 93.52%	1,016 $16.2 Million
Q3 2021 Nov 07, 2023	SELL	$12.68 - $17.79 $963 - $1,352	-76 Reduced 12.65%	525 $8.44 Million
Q2 2021 Nov 07, 2023	SELL	$12.95 - $15.41 $660 - $785	-51 Reduced 7.82%	601 $8.31 Million
Q1 2021 Nov 07, 2023	BUY	$14.42 - $21.39 $1,586 - $2,352	110 Added 20.3%	652 $9.53 Million
Q4 2020 Nov 07, 2023	SELL	$16.56 - $18.94 $4,438 - $5,075	-268 Reduced 33.09%	542 $9.42 Million
Q3 2020 Nov 07, 2023	BUY	$17.41 - $19.89 $4,665 - $5,330	268 Added 49.45%	810 $14.9 Million
Q2 2020 Nov 07, 2023	BUY	$14.43 - $19.16 $7,821 - $10,384	542 New	542 $9.68 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $115M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.